The FDA can ban anything it wants by calling whatever it wants to ban a
And that’s the kicker here: The FDA runs a tight ship when it comes to allowing only
those products on the market from which the agency is able to extort a cut of the profits. If a pharmaceutical drug causes serious side effects or death, for instance, it’s a-okay as long as the
company selling that drug previously paid off the FDA in the form of New Drug Application (NDA) fees. On the other hand, if a completely safe and natural product like CBD is helping millions of
people, the FDA may still choose to ban it by declaring it to be a “drug” that needs to undergo official approval.
In the case of CBD, it’s a natural plant extract that does not require FDA approval
in order to be sold. This means that it also doesn’t have to undergo expensive FDA approval in order to hit store shelves – a situation that time and time again for many different natural products
has resulted in the FDA taking drastic and draconian action against suppliers who dare to sell people therapeutic plant botanicals without the FDA’s official blessing.
Because it works well and isn’t a drug, CBD has been in the crosshairs of the FDA for
years. Back in 2016, the agency reportedly sent out 21 warning letters to companies selling CBD-based products advising them to stop. In 2015, the FDA sent out 15 letters of a similar tone. Though in
the most recent batch of letters, the FDA decided to take an even more aggressive approach to the alleged “illegality” of CBD, which the FDA has erroneously dubbed a “drug.”
“It is a prohibited act under section 301(ll) of the Act (21 U.S.C. 331(ll)) to
introduce or deliver for introduction into interstate commerce any food to which has been added a drug for which substantial clinical investigations have been instituted and for which the existence
of such investigations has been made public, unless the drug was marketed in food before any substantial clinical investigations involving the drug were instituted,” reads the FDA’s statement in each
of the letters.
“The existence of substantial clinical investigations regarding CBD has been made
public. Based on available evidence, FDA has concluded that section 301(ll) prohibits the introduction into interstate commerce of any food to which CBD has been added.”
Follow more news on the healing power of cannabidiols at CBDs.news.
Sources for this article